MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

MDT

95.99

+0.39%↑

VEEV

284.61

+0.57%↑

A

143.05

+0.81%↑

HQY

93.09

+2.08%↑

TLRY

1.56

+0.65%↑

Search

Crinetics Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

42.55 2.31

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

40.66

Максимум

42.77

Ключови измерители

By Trading Economics

Приходи

-19M

-116M

Продажби

670K

1M

Марж на печалбата

-11,216.004

Служители

437

EBITDA

-19M

-129M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+93.89% upside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.6B

4.2B

Предишно отваряне

40.24

Предишно затваряне

42.55

Настроения в новините

By Acuity

50%

50%

141 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.10.2025 г., 20:00 ч. UTC

Придобивния, сливания и поглъщания

Infratil Agrees to NZ$437.7 Million Deal to Raise Contact Energy Stake

19.10.2025 г., 23:44 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Signs of U.S.-China Trade Tensions Easing -- Market Talk

19.10.2025 г., 23:37 ч. UTC

Пазарно говорене

New Zealand's Core CPI Keeps Rate Cut Hopes Alive -- Market Talk

19.10.2025 г., 23:36 ч. UTC

Пазарно говорене

Nikkei May Rise, Tracking Wall Street Gains -- Market Talk

19.10.2025 г., 23:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

19.10.2025 г., 23:09 ч. UTC

Пазарно говорене

Could Rio Tinto, BHP Ally to Defend Iron-Ore Pricing Power? -- Market Talk

19.10.2025 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Luxury Fashion House Kering Confirms Beauty Deal With L'Oréal -- Barrons.com

19.10.2025 г., 22:30 ч. UTC

Печалби

Stock Futures Rise Ahead of Major Week of Earnings -- Barrons.com

19.10.2025 г., 22:18 ч. UTC

Пазарно говорене

Gold at $5,000 on Cards as Investors Get Comfortable -- Market Talk

19.10.2025 г., 21:50 ч. UTC

Пазарно говорене

Infratil's Contact Stake Buy May Require Bigger Asset Sales -- Market Talk

19.10.2025 г., 21:15 ч. UTC

Пазарно говорене

Investors Need to Change Narrative Toward Scales -- Market Talk

19.10.2025 г., 19:34 ч. UTC

Придобивния, сливания и поглъщания

Infratil's Contact Shareholding to Rise to 14.3% When Deal Completes

19.10.2025 г., 19:34 ч. UTC

Придобивния, сливания и поглъщания

Infratil to Issue New Shares Worth NZ$218.8 Million to TECT at NZ$12.43 Each

19.10.2025 г., 19:33 ч. UTC

Придобивния, сливания и поглъщания

Infratil Part-Funding Purchase of Contact Energy Stake With NZ$218.8 Million of Existing Debt

19.10.2025 г., 19:32 ч. UTC

Придобивния, сливания и поглъщания

Infratil Acquiring Additional Contact Energy Stake for NZ$8.95/Share

19.10.2025 г., 19:32 ч. UTC

Придобивния, сливания и поглъщания

Infratil Acquiring Contact Energy Stake for NZ$437.7 Million

19.10.2025 г., 19:31 ч. UTC

Придобивния, сливания и поглъщания

Infratil Acquiring TECT Holdings's Shareholding in Contact Energy

19.10.2025 г., 19:31 ч. UTC

Придобивния, сливания и поглъщания

Infratil to Acquire Additional 4.92% Stake in Contact Energy

19.10.2025 г., 16:29 ч. UTC

Печалби

Elon Musk Pay Drama Heats Up Ahead of Tesla Earnings -- Barrons.com

19.10.2025 г., 11:14 ч. UTC

Печалби

Zijin Mining 3Q Oper Income CNY86.49B; up 8.1% on Year>2899.HK

19.10.2025 г., 11:14 ч. UTC

Печалби

Zijin Mining: Higher Sales of Gold, Copper Supported Results >2899.HK

19.10.2025 г., 11:14 ч. UTC

Печалби

Zijin Mining 3Q Net CNY14.57B; up 57.1% on Year>2899.HK

18.10.2025 г., 13:30 ч. UTC

Придобивния, сливания и поглъщания

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18.10.2025 г., 13:30 ч. UTC

Придобивния, сливания и поглъщания

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18.10.2025 г., 13:30 ч. UTC

Придобивния, сливания и поглъщания

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18.10.2025 г., 13:30 ч. UTC

Придобивния, сливания и поглъщания

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18.10.2025 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

17.10.2025 г., 23:25 ч. UTC

Придобивния, сливания и поглъщания

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17.10.2025 г., 22:15 ч. UTC

Пазарно говорене

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17.10.2025 г., 21:15 ч. UTC

Пазарно говорене

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Crinetics Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

93.89% нагоре

12-месечна прогноза

Среден 80.6 USD  93.89%

Висок 143 USD

Нисък 40 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за Crinetics Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

15

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

30.39 / 33.46Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

141 / 371 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat